Sad truths from a New York Times article on an experimental Ebola vaccine that had been successfully tested with monkeys to great fanfare and then sat on a shelf untested on humans for almost ten years…
Its development stalled in part because Ebola is rare, and until now, outbreaks had infected only a few hundred people at a time. But experts also acknowledge that the lack of follow-up on such a promising candidate reflects a broader failure to produce medicines and vaccines for diseases that afflict poor countries. Most drug companies have resisted spending the enormous sums needed to develop products useful mostly to countries with little ability to pay.
Credit: Wikimedia
